Acute kidney injury (AKI), also known as acute kidney failure (ARF), is a common and complex kidney disease in clinic and an important factor related to poor prognosis of patients in clinic. In the present study, a single-center retrospective study was conducted in our center. The clinical data of hospitalized patients received β-Lactam drugs from January 2018 to December 2020 was retrospectively analyzed. The multiple logistic regression analysis suggested that complicated with hypertension, anemia, pneumonia, shock, sepsis, heart failure, combined use of proton pump inhibitors (PPI), angiotensin-converting enzyme inhibitor (ACEI), angiotensin Ⅱ receptor antagonist (ARB) were independent risk factors for AKI related to β-Lactam drugs. In clinical practice, patients with acute kidney injury risk factors should be closely monitored for changes in their blood creatinine and urine output to avoid acute kidney injury. For patients who have suffered from acute kidney injury, the cause should be removed in time and corresponding symptomatic treatment should be given.
Study Type
OBSERVATIONAL
Enrollment
19,000
During hospitalization，patients used Beta-Lactam drugs.
Xiao Li，MD
Jinan, Shandong, China
The incidence of acute kidney injury in hospitalized patients treated with β-lactam drugs
To analyze the incidence of acute kidney injury in hospitalized patients after using β-lactam drugs and to build a prediction model.
Time frame: Through study completion，up to half a year.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.